Hepatitis C Treatment, Trials and you:
New, exciting breakthroughs in the treatment of liver disease mean less time and higher cure rates!In Marty's case, merely feeling unwell enough to go to his primary care physician found only edema, but blood labs said Chronic Hepatitis C with levels showing highly active virus.
With treatment apparently urgent, his doctor found a research trial ongoing at Scripps in San Diego that was testing Teleprevir from Vertex Pharmaceuticals. The trial required a liver biopsy and the insurance company was receptive, so with time of the essence the liver biopsy showed both necrosis and sclerosis: treatment or premature death. . .
While also taking Interferon and Ribivarin, Marty endured those side effects while having weely blood tests to see if the Teleprevir was starving the Hepatitis C virus. Dosing was every 8 hours for twelve weeks, and at seven months he was feeling well enough to be confident of recovery. Today he can enjoy his family and even successfully bow hunt for deer.
Accredo Specialty Pharmacy Releases Mobile App for Hepatitis C PatientsWednesday June 25, 2014 6:40am PDT
ST. LOUIS, June 24, 2014 /PRNewswire/ -- Accredo Specialty Pharmacy has recently launched Accredo Plus C , a new iOS app that empowers hepatitis C patients to take control, better manage their treatment and increase adherence.
Accredo Plus C is a free iPhone app available to all hepatitis C patients, regardless of pharmacy or insurance provider. The app was created by pharmacists and nurses that specialize in counseling hepatitis C patients. It leverages their disease-specific expertise to help patients derive the most out of their therapy by increasing adherence.
The app includes unique features designed specifically for hepatitis C patients and includes all hep C medications currently on the market.
Download Accredo Plus C today from the App Store or visit http://www.AccredoPlusC.com to view screenshots and learn more about the app.
Understanding Hep C Treatment The goal of hep C treatment is to achieve a Sustained Virologic Response – meaning absence of the virus for six months or longer following therapy completion. Patients who fail to take their full regimen of medications exactly as their physician prescribes are at risk of therapy failure and long-term consequences including liver cancer and cirrhosis. Additionally, undergoing only a partial regimen may make future therapies less effective.
Contact: Riddhi Trivedi, 314-684-6665, RTrivedi-St.Clair@express-scripts.com
SOURCE Accredo Specialty Pharmacy
Copyright © 2014 PR Newswire. All rights reserved
Johns Hopkins Viral Hepatitis Center NewsFri May 9, 2014 7:34am PDT
Visit the Johns Hopkins Viral Hepatitis Center facebook page >>
FDA approves Gilead's breakthrough hepatitis C pillFri Dec 6, 2013 6:34pm EST
(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi, also known as sofosbuvir, as a potential cure for chronic infection with the liver-destroying hepatitis C virus.
The once-a-day pill is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms.
Hepatitis C, which is often undiagnosed, affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer.
Most patients will be treated with the $7,000-a-week drug for 12 weeks, resulting in a total price of $84,000, according to Gilead spokeswoman Cara Miller.
"Today marks a landmark advance in the treatment of hepatitis C, opening up new opportunities to stop the spread of this virus and the ravages of this disease," Dr John Ward, director of the Centers for Disease Control and Prevention's division of viral hepatitis, said in a statement.
Last year, the CDC recommended that all baby boomers, born from 1945 to 1965, be tested for the virus. Introduction of blood and organ screening in the 1990s has dramatically lowered infection rates for younger generations.